Aromatic organic compounds as scaffolds for metallocarboxypeptidase inhibitor design

Chemical Biology and Drug Design

Volumn 73, Issue 1, 2009, Pages 75-82

  Fernández, Daniel ^a   Avilés, Francesc X ^a   Vendrell, Josep ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aromatic organic derivative; Enzyme inhibition; Human carboxypeptidase B; In silico screening; Metallocarboxypeptidases; Molecular docking

Indexed keywords

2 [5 [(NAPHTHALEN 2 YLOXY)METHYL] 1,3,4 OXADIAZOL 2 YLTHIO] 1 (4 TOLYL)ETHANONE; AROMATIC COMPOUND; CARBOXYPEPTIDASE B; LIGAND; METALLOCARBOXYPEPTIDASE INHIBITOR; NAPHTHALENE DERIVATIVE; PROTEINASE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; CORRELATION ANALYSIS; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CARBOXYPEPTIDASES; DRUG DESIGN; HUMANS; METALLOPROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; ORGANIC CHEMICALS; PROTEIN CONFORMATION; QUINAZOLINES; QUINOLINES; RECOMBINANT PROTEINS;

EID: 58149084494     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00752.x     Document Type: Article

References (40)

1. Dunn F.W., Dittmer K. (1950) Action of carboxypeptidase toward peptides containing unnatural aromatic amino acids. Science 111 : 173 175.
2. Park J.D., Kim D.H. (2002) Cysteine derivatives as inhibitors for carboxypeptidase A: synthesis and structure-activity relationships. J Med Chem 45 : 911 918.
3. Martin M.T., Holmquist B., Riordan J.F. (1989) An angiotensin converting enzyme inhibitor is a tight-binding slow substrate of carboxypeptidase A. J Inorg Biochem 36 : 39 50.
4. Lanthier C.M., Parniak M.A., Dmitrenko G.I. (1997) Inhibition of carboxypeptidase A by n-(4-t-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Bioorg Med Chem Lett 7 : 1557 1562.
5. Latt S.A., Auld D.S., Vallee B.L. (1972) Fluorescende determination of carboxypeptidase A activity based on electronic energy transfer. Anal Biochem 50 : 56 62.
6. Yajima R., Chikuma T., Kato T. (1995) Highly sensitive high-performance liquid chromatography-fluorimetric assay method for carboxypeptidase H activity. J Chromatogr B Biomed Appl 667 : 333 338.
7. Vogel W.H., Snyder R., Schulman M.P. (1964) Inhibition of several enzymes by folic acid, aminopterin and amethopterin. Biochim Biophys Acta 85 : 164 166.
8. Vogel W.H., Snyder R., Schulman M.P. (1964) Effects of aromatic and nonaromatic model compounds and drugs on enzymic activities. J Pharmacol Exp Ther 146 : 66 73.
9. Vendrell J., Aviles F.X., Fricker L.D. (2004) Metallocarboxypeptidases. In : Messerschmidt A., Bode W., Cygler M., editors. Metallocarboxypeptidases. Chichester : John Wiley & Sons, Ltd p. 176 189.
10. Rodriguez de la Vega M., Sevilla R.G., Hermoso A., Lorenzo J., Tanco S., Diez A., Fricker L.D., Bautista J.M., Aviles F.X. (2007) Nna1-like proteins are active metallocarboxypeptidases of a new and diverse M14 subfamily. FASEB J 21 : 851 865.
11. Matsugi S., Hamada T., Shioi N., Tanaka T., Kumada T., Satomura S. (2007) Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. Clin Chim Acta 378 : 147 153.
12. Shamamian P., Goldberg J.D., Ye X.Y., Stewart J.D., White P.J., Gilvarg C. (2006) Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. HPB (Oxford) 8 : 451 457.
13. Rooth E., Wallen H., Antovic A., von Arbin M., Kaponides G., Wahlgren N., Blomback M., Antovic J. (2007) Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis 18 : 365 370.
14. Willemse J.L., Hendriks D.F. (2007) A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci 12 : 1973 1987.
15. Arolas J.L., Vendrell J., Aviles F.X., Fricker L.D. (2007) Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr Pharm Des 13 : 349 366.
16. Mittl P.R., Grutter M.G. (2006) Opportunities for structure-based design of protease-directed drugs. Curr Opin Struct Biol 16 : 769 775.
17. Barrow J.C., Nantermet P.G., Stauffer S.R., Ngo P.L., Steinbeiser M.A., Mao S.S., Carroll S.S. et al. (2003) Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem 46 : 5294 5297.
18. Buchanan M.S., Carroll A.R., Edser A., Sykes M., Fechner G.A., Forster P.I., Guymer G.P., Quinn R.J. (2008) Lysianadioic acid, a carboxypeptidase B inhibitor from Lysiana subfalcata. Bioorg Med Chem Lett 18 : 1495 1497.
19. Suzuki K., Muto Y., Fushihara K., Kanemoto K., Iida H., Sato E., Kikuchi C., Matsushima T., Kato E., Nomoto M., Yoshioka S., Ishii H. (2004) Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3- phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 309 : 607 615.
20. Kallus C., Broenstrup M., Czechtizky W., Evers A., Follmann M., Halland N., Schreuder H. (2008) Urea and sulfamide derivatives as TAFIA inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases, WO Patent No. 2008067909.
21. Wang Y.X., Zhao L., Nagashima M., Vincelette J., Sukovich D., Li W., Subramanyam B. et al. (2007) A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost 97 : 45 53.
22. Wang Y.X., da Cunha V., Vincelette J., Zhao L., Nagashima M., Kawai K., Yuan S., Emayan K., Islam I., Hosoya J., Sullivan M.E., Dole W.P., Morser J., Buckman B.O., Vergona R. (2007) A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 97 : 54 61.
23. Bayes A., de la Vega M.R., Vendrell J., Aviles F.X., Jongsma M.A., Beekwilder J. (2006) Response of the digestive system of Helicoverpa zea to ingestion of potato carboxypeptidase inhibitor and characterization of an uninhibited carboxypeptidase B. Insect Biochem Mol Biol 36 : 654 664.
24. Bayes A., Comellas-Bigler M., Rodriguez de la Vega M., Maskos K., Bode W., Aviles F.X., Jongsma M.A., Beekwilder J., Vendrell J. (2005) Structural basis of the resistance of an insect carboxypeptidase to plant protease inhibitors. Proc Natl Acad Sci USA 102 : 16602 16607.
25. Pallares I., Fernandez D., Comellas-Bigler M., Fernandez-Recio J., Ventura S., Aviles F.X., Bode W., Vendrell J. (2008) Direct interaction between a human digestive protease and the mucoadhesive poly(acrylic acid). Acta Crystallogr D Biol Crystallogr 64 : 784 791.
26. Barbosa Pereira P.J., Segura-Martin S., Oliva B., Ferrer-Orta C., Aviles F.X., Coll M., Gomis-Ruth F.X., Vendrell J. (2002) Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol 321 : 537 547.
27. Turk B. (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5 : 785 799.
28. Kaplan H.R., Cohen D.M., Essenburg A.D., Major T.C., Mertz T.E., Ryan M.J. (1984) CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed Proc 43 : 1326 1329.
29. Roehrborn C.G., Siegel R.L. (1996) Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 48 : 406 415.
30. Ventura S., Villegas V., Sterner J., Larson J., Vendrell J., Hershberger C.L., Aviles F.X. (1999) Mapping the pro-region of carboxypeptidase B by protein engineering. Cloning, overexpression, and mutagenesis of the porcine proenzyme J Biol Chem 274 : 19925 19933.
31. Gasteiger J., Rudolph C., Sadowski J. (1990) Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Comput Methodol 3 : 537 547.
32. Miteva M.A., Violas S., Montes M., Gomez D., Tuffery P., Villoutreix B.O. (2006) FAF-drugs: free ADME/tox filtering of compound collections. Nucleic Acids Res 34 : W738 W744.
33. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19 : 1639 1662.
34. Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50 : 760 776.
35. Krier M., Bret G., Rognan D. (2006) Assessing the scaffold diversity of screening libraries. J Chem Inf Model 46 : 512 524.
36. Joy S., Nair P.S., Hariharan R., Pillai M.R. (2006) Detailed comparison of the protein-ligand docking efficiencies of GOLD, a commercial package and ArgusLab, a licensable freeware. In Silico Biol 6 : 601 605.
37. Rewinkel J.B., Lucas H., Smit M.J., Noach A.B., van Dinther T.G., Rood A.M., Jenneboer A.J., van Boeckel C.A. (1999) Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett 9 : 2837 2842.
38. Rewinkel J.B., Lucas H., van Galen P.J., Noach A.B., van Dinther T.G., Rood A.M., Jenneboer A.J., van Boeckel C.A. (1999) 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg Med Chem Lett 9 : 685 690.
39. Fernandez D., Illa O., Aviles F.X., Branchadell V., Vendrell J., Ortuno R.M. (2008) Thioxophosphoranyl aryl- and heteroaryloxiranes as the representants of a new class of metallocarboxypeptidase inhibitors. Bioorg Med Chem 16 : 4823 4828.
40. Cheng Y., Prusoff W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099 3108.